Abstract:Surgical intervention for stage IV non-small cell lung cancer (NSCLC) is still controversial. This study sought to evaluate the clinical effects of surgical intervention on survival in patients with stage IV NSCLCs and to identify the cohort benefitting the most from surgery.A retrospective study from the Surveillance, Epidemiology, and End Results database was performed to compare the survival of stage IV NSCLC patients who had undergone surgery with those who did not undergo surgery. Overall survival (OS) was evaluated using the Kaplan-Meier method and the log-rank test. The Cox proportional hazards model was used for multivariate analysis.The total number of eligible patients was 43,538, including 16.8% in the M1a stage and 83.2% in the M1b stage. The percentages of patients with no surgery (NONE), only metastatic tumor resection (MTR), only primary tumor resection (PTR), and both primary and metastatic tumor resection (PMTR) were 89.0%, 6.7%, 3.5%, and 0.8%, respectively; the corresponding 5-year survival rates were 2.0%, 4.0%, 13.0%, and 20.0%, respectively (P < 0.001); and the corresponding OS rates were 11.1 months, 14.7 months, 29.4 months, and 34.9 months, respectively (P < 0.001). Notably, the pairwise comparisons of 5-year survival rate and OS among the subgroups were all statistically significant. The multivariate analysis showed that surgical intervention was correlated with longer survival in patients with stage IV NSCLC. The stratified analysis showed significant differences in the OS on strata of the M1a stage and strata of the M1b stage. In the M1a stage, patients with PTR had significantly better OS than those with NONE (P < 0.001) or MTR (P < 0.001) but showed no significant differences compared with those with PMTR (P = 0.174); patients with MTR did not have prolonged survival compared with patients with NONE (P = 0.185), and they also did not have prolonged survival compared with patients with PMTR (P = 0.052). In the M1b stage, pairwise comparisons of OS were all statistically significant among the subgroups (P < 0.001).Surgical intervention can prolong survival to different degrees according to the modalities of surgery in stage IV NSCLC.

Role of surgery for stage IIIA-N2 non-small cell lung cancer.

The Role of Surgery in the Treatment of Stage III_A Non-small-cell Lung Cancer

Surgical challenges in multimodal treatment of N2-stage IIIA non-small cell lung cancer

Stage III N2 non-small cell lung cancer treatment: decision-making among surgeons and radiation oncologists

Postoperative radiotherapy for patients with completely resected stage IIIA-N2 non-small cell lung cancer: opt-in or opt-out

Expert Consensus on Treatment for Stage III Non‐small Cell Lung Cancer

Surgical Intervention Improves Survival for Metastatic Non-Small Cell Lung Cancer Patients.

Real-world Surgical Treatment Patterns and Clinical Outcomes in Patients with Stages IA–IIIA Non-Small Cell Lung Cancer: a Retrospective Multicentric Observational Study Involving 11,958 Patients

Trimodal therapy and surgical approaches in stage IIIA/N2 non-small cell lung cancer

Retrospective Study of Surgery Versus Non-Surgical Management in Limited-Disease Small Cell Lung Cancer

Resectable non-stage IV nonsmall cell lung cancer: the surgical perspective

Is there role of adjuvant radiotherapy after complete resection of locally advanced nonsmall cell lung cancer?

Long-Term Outcomes of Selected Patients with IIIA–N2 Non-small Cell Lung Cancer Receiving Upfront Surgical Resection

Risks of neoadjuvant chemotherapy and radiation therapy

Therapeutic Strategies for Resectable Stage-IIIA N2 Non-Small Cell Lung Cancer Patients: A Network Meta-Analysis

[Survival Analysis of 121 Stage N2-IIIa Non-small Cell Lung Cancer Patients Treated with Surgery].

Patients With Surgically Resectable Lung Cancer Who Opt for Radiation Have Worse Outcomes

Retrospective study of surgical resection in the treatment of limited stage small cell lung cancer

Stereotactic body radiotherapy or stereotactic ablative radiotherapy versus surgery for patients with T1-3N0M0 non-small cell lung cancer: a systematic review and meta-analysis.

Choice of Treatment for Patients with Non–small-cell Lung Cancer >5 Cm Between Surgery Alone and Surgery Plus Adjuvant Radiotherapy

Comparison between radiofrequency ablation and sublobar resections for the therapy of stage I non-small cell lung cancer: a meta-analysis